[The Update and the Future of Antiangiogentic Agents].
Shinichi
S
Togami
Hiroaki
H
Kobayashi
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab